Literature DB >> 11465092

Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.

J A Kovacs1, S Vogel, J A Metcalf, M Baseler, R Stevens, J Adelsberger, R Lempicki, R L Hengel, I Sereti, L Lambert, R L Dewar, R T Davey, R E Walker, J Falloon, M A Polis, H Masur, H C Lane.   

Abstract

To characterize the immunological effects of intermittent IL-2 therapy, which leads to selective increases in CD4+ T lymphocytes in HIV-infected patients, 11 patients underwent extensive immunological evaluation. While IL-2 induced changes in both CD4+ and CD8+ cell number acutely, only CD4+ cells showed sustained increases following discontinuation of IL-2. Transient increases in expression of the activation markers CD38 and HLA-DR were seen on both CD4+ and CD8+ cells, but CD25 (a chain of the IL-2 receptor) increased exclusively on CD4+ cells. This increase in CD25 expression was sustained for months following discontinuation of IL-2, and was seen in naive as well as memory cells. IL-2 induced cell proliferation, but tachyphylaxis to these proliferative effects developed after 1 week despite continued IL-2 administration. It thus appears that sustained CD25 expression selectively on CD4+ cells is a critical component of the immunological response to IL-2, and that intermittent administration of IL-2 is necessary to overcome the tachyphylaxis to IL-2-induced proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465092     DOI: 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  Effects of exogenous IL-2 administration on the homeostasis of CD4+ T lymphocytes.

Authors:  Arnaud Foussat; Laurence Bouchet-Delbos; Jacques Couderc; Dominique Berrebi; Michèle German-Fattal; Marie-Christine Maillot; Ingrid Durand-Gasselin; Pierre Galanaud; James P Di Santo; Dominique Emilie
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

2.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Authors:  John M Wrangle; Vamsidhar Velcheti; Manish R Patel; Elizabeth Garrett-Mayer; Elizabeth G Hill; James G Ravenel; Jeffrey S Miller; Mohammad Farhad; Kate Anderton; Kathryn Lindsey; Michele Taffaro-Neskey; Carol Sherman; Samantha Suriano; Marzena Swiderska-Syn; Amy Sion; Joni Harris; Andie R Edwards; Julie A Rytlewski; Catherine M Sanders; Erik C Yusko; Mark D Robinson; Carsten Krieg; William L Redmond; Jack O Egan; Peter R Rhode; Emily K Jeng; Amy D Rock; Hing C Wong; Mark P Rubinstein
Journal:  Lancet Oncol       Date:  2018-04-05       Impact factor: 41.316

Review 3.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

Review 4.  CD4+ T-cell depletion in HIV infection: killed by friendly fire?

Authors:  Abeer Moanna; Richard Dunham; Mirko Paiardini; Guido Silvestri
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

5.  Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.

Authors:  Michele Di Mascio; Irini Sereti; Lynn T Matthews; Ven Natarajan; Joseph Adelsberger; Richard Lempicki; Christian Yoder; Elizabeth Jones; Catherine Chow; Julia A Metcalf; Igor A Sidorov; Dimiter S Dimitrov; Michael A Polis; Joseph A Kovacs
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.

Authors:  M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.

Authors:  Ven Natarajan; Richard A Lempicki; Irini Sereti; Yunden Badralmaa; Joseph W Adelsberger; Julia A Metcalf; Darue A Prieto; Randy Stevens; Michael W Baseler; Joseph A Kovacs; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

8.  IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Authors:  Irini Sereti; Richard M Dunham; John Spritzler; Evgenia Aga; Michael A Proschan; Kathy Medvik; Catherine A Battaglia; Alan L Landay; Savita Pahwa; Margaret A Fischl; David M Asmuth; Allan R Tenorio; John D Altman; Lawrence Fox; Susan Moir; Angela Malaspina; Michel Morre; Renaud Buffet; Guido Silvestri; Michael M Lederman
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

9.  Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.

Authors:  Brian O Porter; Kara B Anthony; Jean Shen; Barbara Hahn; Chris E Keh; Frank Maldarelli; William C Blackwelder; Henry Clifford Lane; Joseph A Kovacs; Richard T Davey; Irini Sereti
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

Review 10.  The lymph node in HIV pathogenesis.

Authors:  Michael M Lederman; Leonid Margolis
Journal:  Semin Immunol       Date:  2008-07-14       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.